Neutropenia Associated with Immunizations

Definition and Clinical Significance

• Neutropenia is considered clinically significant when the absolute neutrophil count (ANC) falls below 500 cells/mm³, or below 1000 cells/mm³ with a predicted decline to ≤500/mm³ over the next 48 hours, as defined by the National Comprehensive Cancer Network 1

Risk Factors and Management

• Concurrent use of medications with known myelosuppressive effects can increase the risk of vaccine-associated neutropenia, according to the American Academy of Dermatology 2
• For mild to moderate neutropenia without fever or signs of infection, routine monitoring is generally sufficient, as recommended by medical guidelines 3
• In patients with severe neutropenia (<500 cells/mm³) or neutropenia with fever, prompt evaluation for infection is warranted, and empiric broad-spectrum antibiotics should be considered, as advised by the Infectious Diseases Society of America 4 and the European Society for Medical Oncology 5
• Granulocyte colony-stimulating factor (G-CSF) may be considered in cases of severe, prolonged neutropenia, as suggested by the European Society for Medical Oncology 5 and 6

Special Populations

• In cancer patients receiving CAR T-cell therapy, neutropenia is common and may follow a biphasic pattern with initial recovery followed by a "second dip", as observed by the European Society for Medical Oncology 5 and 6
• In patients with autoimmune conditions like systemic lupus erythematosus (SLE), vaccination generally does not significantly alter neutrophil counts, though other immunological parameters may be affected, according to the European League Against Rheumatism 7 and 8